<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="92160"><DrugName>relacorilant</DrugName><DrugNamesKey><Name id="43094281">relacorilant</Name></DrugNamesKey><DrugSynonyms><Name><Value>relacorilant</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>CORT-125134</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>1496510-51-0</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="28807">Corcept Therapeutics Inc</CompanyOriginator><CompaniesPrimary><Company id="28807">Corcept Therapeutics Inc</Company></CompaniesPrimary><CrossReferences><SourceEntity id="28807" type="Company"><TargetEntity id="4295899705" type="organizationId">Corcept Therapeutics Inc</TargetEntity></SourceEntity><SourceEntity id="1005" type="ciIndication"><TargetEntity id="1570" type="siCondition"/><TargetEntity id="4148" type="siCondition"/></SourceEntity><SourceEntity id="2243" type="ciIndication"><TargetEntity id="C57.0" type="ICD10"/><TargetEntity id="10016180" type="MEDDRA"/><TargetEntity id="D005185" type="MeSH"/><TargetEntity id="-33569282" type="omicsDisease"/><TargetEntity id="600" type="siCondition"/></SourceEntity><SourceEntity id="249" type="ciIndication"><TargetEntity id="C25" type="ICD10"/><TargetEntity id="10033609" type="MEDDRA"/><TargetEntity id="D010190" type="MeSH"/><TargetEntity id="-670361033" type="omicsDisease"/><TargetEntity id="630" type="siCondition"/></SourceEntity><SourceEntity id="3083" type="ciIndication"><TargetEntity id="C48" type="ICD10"/><TargetEntity id="10061344" type="MEDDRA"/><TargetEntity id="D010534" type="MeSH"/><TargetEntity id="-745704479" type="omicsDisease"/><TargetEntity id="633" type="siCondition"/></SourceEntity><SourceEntity id="3246" type="ciIndication"><TargetEntity id="3031" type="siCondition"/></SourceEntity><SourceEntity id="3484" type="ciIndication"><TargetEntity id="E24" type="ICD10"/><TargetEntity id="10011652" type="MEDDRA"/><TargetEntity id="D003480" type="MeSH"/><TargetEntity id="553" type="ORPHANET"/><TargetEntity id="-1380874501" type="omicsDisease"/><TargetEntity id="505" type="siCondition"/></SourceEntity><SourceEntity id="49" type="ciIndication"><TargetEntity id="C50" type="ICD10"/><TargetEntity id="10006279" type="MEDDRA"/><TargetEntity id="D001943" type="MeSH"/><TargetEntity id="-436099203" type="omicsDisease"/><TargetEntity id="588" type="siCondition"/></SourceEntity><SourceEntity id="725" type="ciIndication"><TargetEntity id="1164" type="siCondition"/></SourceEntity><SourceEntity id="799" type="ciIndication"><TargetEntity id="C56" type="ICD10"/><TargetEntity id="10033128" type="MEDDRA"/><TargetEntity id="D010051" type="MeSH"/><TargetEntity id="-1370909262" type="omicsDisease"/><TargetEntity id="626" type="siCondition"/></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity></SourceEntity><SourceEntity id="1886" type="Action"><TargetEntity id="1739" type="Mechanism">Glucocorticoid Receptor (GR) Antagonists</TargetEntity><TargetEntity id="804" type="Mechanism">Antiglucocorticoids</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C3">Phase 3 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="2243">Fallopian tube cancer</Indication><Indication id="249">Pancreas tumor</Indication><Indication id="3083">Peritoneal tumor</Indication><Indication id="3246">Hormone refractory prostate cancer</Indication><Indication id="3484">Cushings syndrome</Indication><Indication id="49">Breast tumor</Indication><Indication id="725">Solid tumor</Indication><Indication id="799">Ovary tumor</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1005">Unidentified indication</Indication></IndicationsSecondary><ActionsPrimary><Action id="1886">Glucocorticoid receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="586">Capsule formulation</Technology></Technologies><LastModificationDate>2019-06-04T04:21:11.000Z</LastModificationDate><ChangeDateLast>2019-06-05T00:00:00.000Z</ChangeDateLast><AddedDate>2014-08-06T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="28807" linkType="Company"&gt;Corcept Therapeutics&lt;/ulink&gt; is developing relacorilant (CORT-125134), a selective  glucocorticoid receptor antagonist, for the potential oral treatment of Cushing's syndrome, solid tumors, metastatic castration resistant prostate cancer (mCRPC), recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer [&lt;ulink linkID="1583174" linkType="Reference"&gt;1583174&lt;/ulink&gt;], [&lt;ulink linkID="1608587" linkType="Reference"&gt;1608587&lt;/ulink&gt;], [&lt;ulink linkID="1630027" linkType="Reference"&gt;1630027&lt;/ulink&gt;],  [&lt;ulink linkID="1775589" linkType="Reference"&gt;1775589&lt;/ulink&gt;], [&lt;ulink linkID="2075548" linkType="Reference"&gt;2075548&lt;/ulink&gt;], [&lt;ulink linkID="2105732" linkType="Reference"&gt;2105732&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;in October 2018, a phase III trial in Cushing's syndrome (GRACE) was initiated [&lt;ulink linkID="2081471" linkType="Reference"&gt;2081471&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By  April 2016, a phase I/II trial in solid tumors had been initiated [&lt;ulink linkID="1757177" linkType="Reference"&gt;1757177&lt;/ulink&gt;]; in December 2017, the company  opened an efficacy  cohort in patients with pancreatic cancer [&lt;ulink linkID="2011328" linkType="Reference"&gt;2011328&lt;/ulink&gt;]; in February 2018,  expansion cohorts in patients with ovarian and triple-negative breast cancer were expected to open later in 2018 [&lt;ulink linkID="2007707" linkType="Reference"&gt;2007707&lt;/ulink&gt;]; in June 2018, positive preliminary data from the initial, dose-finding portion of the trial were presented  [&lt;ulink linkID="2039437" linkType="Reference"&gt;2039437&lt;/ulink&gt;], [&lt;ulink linkID="2041222" linkType="Reference"&gt;2041222&lt;/ulink&gt;]. In January 2019, a phase II study was  initiated in patients  with recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer treated with intermittent or continuous regimens of relacorilant in combination with nab-paclitaxel [&lt;ulink linkID="2105732" linkType="Reference"&gt;2105732&lt;/ulink&gt;].  In October 2018, a phase I trial was initiated in mCRPC [&lt;ulink linkID="2075548" linkType="Reference"&gt;2075548&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;In November 2018, Corcept noted that issued patents covering relacorilant's composition of matter and method of use  expire in 2033 [&lt;ulink linkID="2096366" linkType="Reference"&gt;2096366&lt;/ulink&gt;]. &lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In September 2018, the FDA granted Orphan Drug designation for pancreatic cancer [&lt;ulink linkID="2077891" linkType="Reference"&gt;2077891&lt;/ulink&gt;], [&lt;ulink linkID="2114340" linkType="Reference"&gt;2114340&lt;/ulink&gt;]. In October 2018, the FDA granted Orphan designation for endogenous Cushing syndrome [&lt;ulink linkID="2114344" linkType="Reference"&gt;2114344&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In April 2019, the EMA recommended granting Orphan designation for relacorilant to treat patients with Cushing's syndrome [&lt;ulink linkID="2150182" linkType="Reference"&gt;2150182&lt;/ulink&gt;], [&lt;ulink linkID="2151157" linkType="Reference"&gt;2151157&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Cushing's syndrome&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In August 2017, end-of phase II meeting with the FDA and phase III trial were planned [&lt;ulink linkID="1949941" linkType="Reference"&gt;1949941&lt;/ulink&gt;]; in November 2017, a phase III trial was planned for the third quarter of 2018 [&lt;ulink linkID="1977706" linkType="Reference"&gt;1977706&lt;/ulink&gt;]. In February 2018, phase III trial was expected to start in 2H18 [&lt;ulink linkID="2007690" linkType="Reference"&gt;2007690&lt;/ulink&gt;]. In May 2018, based on safety and efficacy data from the low and high dose cohorts of phase II trial, accelerated preparations for a phase III trial for Cushing's syndrome were underway [&lt;ulink linkID="2031871" linkType="Reference"&gt;2031871&lt;/ulink&gt;]. In October 2018, phase III study was expected to start by the end of 2018 [&lt;ulink linkID="2077891" linkType="Reference"&gt;2077891&lt;/ulink&gt;]. Later that month, a double-blind, parallel assigned, placebo-controlled, randomized-withdrawal, phase III trial (&lt;ulink linkID="355712" linkType="Protocol"&gt;NCT03697109&lt;/ulink&gt;; CORT125134-455; GRACE) was to begin in October 2018 in the US, in patients (expected  n = 130) with endogenous Cushing syndrome and concurrent Type 2 diabetes mellitus/impaired glucose tolerance and/or uncontrolled hypertension, to assess the safety and efficacy of relacorilant. The primary endpoint was the assessment of safety based on treatment-emergent adverse events (TEAEs) as graded by CTCAE v5.0; the mean change from Week OL22 to Week RW12 or Early Termination (ET) in the 2-hour oGTT glucose (mg/dL) in patiients with diabetes mellitus/impaired glucose tolerance (DM/IGT); and  the proportion of patients with an increase in systolic or diastolic blood pressure of at least 5 mmHg or any increase in antihypertensive medication from OL22 to RW12/ET in patients with hypertension. The trial was expected to complete in January 2021. At that time, an extension study of the trial was to be initiated [&lt;ulink linkID="2081471" linkType="Reference"&gt;2081471&lt;/ulink&gt;]. Later that month, the trial was initiated [&lt;ulink linkID="2081471" linkType="Reference"&gt;2081471&lt;/ulink&gt;]. In November 2018, the first patient was dosed [&lt;ulink linkID="2096366" linkType="Reference"&gt;2096366&lt;/ulink&gt;]. In February 2019, the study was underway in the US, Canada, Europe and Israel [&lt;ulink linkID="2123079" linkType="Reference"&gt;2123079&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In June 2016, an open-label, single group assignment, phase II trial (&lt;ulink linkID="263586" linkType="Protocol"&gt;NCT02804750&lt;/ulink&gt;; CORT125134-451) was initiated in the US, in patients (expected  n = 30) with endogenous Cushing's syndrome, to assess the safety and efficacy of oral relacorilant. The primary endpoint was general safety of the drug at 12 months. At that time, the trial was to complete in December 2017. By December 2016, the trial was recruiting in Hungary and the UK [&lt;ulink linkID="1775589" linkType="Reference"&gt;1775589&lt;/ulink&gt;]. The trial was being conducted under a clinical trial agreement with &lt;ulink linkID="1041758" linkType="Company"&gt;Chiltern&lt;/ulink&gt; [&lt;ulink linkID="1912768" linkType="Reference"&gt;1912768&lt;/ulink&gt;]. In May 2017, enrollment of patients was underway [&lt;ulink linkID="1922913" linkType="Reference"&gt;1922913&lt;/ulink&gt;]. In February 2018, interim  results  from the first 17 patients enrolled in the low-dose cohort  were reported. Each patient received 100 mg/day of relacorilant for four weeks, then 150 mg/day for four weeks, then 200 mg/day for four weeks. Statistically significant, dose-dependent improvements in glucose tolerance and serum osteocalcin were observed. In addition a 5 mm or greater reduction in systolic or diastolic	 BP was observed in 45% of patients with uncontrolled hypertension. Levels of osteocalcin were improved. There was no evidence of progesterone receptor affinity. At that time, testing of higher doses was continued [&lt;ulink linkID="2007690" linkType="Reference"&gt;2007690&lt;/ulink&gt;]. In May 2018, enrollment was completed in high dose cohort and full data were expected in 3Q18 [&lt;ulink linkID="2031871" linkType="Reference"&gt;2031871&lt;/ulink&gt;]. In August 2018, interim data from high dose cohort at eight weeks of treatment (conclusion of the 300 mg dose level) were reported. 58% of patients with hyperglycemia achieved improved glucose control, as shown by a (i) 0.5% or greater reduction in HbA1c or (ii) 50 mg/dl or greater reduction (or normalization) in 2-hour glucose as measured in the oral glucose tolerance test or (iii) 25% or greater decrease in antidiabetic medications. 55% of patients with uncontrolled hypertension achieved a five millimeter or greater drop in either systolic or diastolic blood pressure, as measured by 24-hour ambulatory monitoring. There was no evidence of progesterone receptor affinity and  no instances of hypokalemia. At that time, testing of higher doses was ongoing [&lt;ulink linkID="2062169" linkType="Reference"&gt;2062169&lt;/ulink&gt;]. In February 2019,  further data showed that the drug was well tolerated  in the trial [&lt;ulink linkID="2123079" linkType="Reference"&gt;2123079&lt;/ulink&gt;]. In March 2019, further data were presented from two patients with Cushing disease due to pituitary macroadenomas at the 2019 Endocrine Society Annual Meeting in New Orleans, LA. Female and male patients received relacorilant qd dose 100 mg at week 1 to 4, 150 mg at week 5 to 8, and 200 mg at week 9 to 12, as a preoperative therapy. Pituitary tumor decreased from 10 x 6.3 to 8.0 x 5.7 mm in female patient and from 22 x 25 x 26 to 21 x 22 x 19 mm in male patient after treatment with relacorilant.  ACTH levels did not change and remained consistent with baseline (at week 4, 8 and 12: female patient: 12.9, 13.3 and 14.9 pM and male patient: 25.5, 30.2 and 26 pM, respectively) [&lt;ulink linkID="2131152" linkType="Reference"&gt;2131152&lt;/ulink&gt;]. In April 2019, further data were presented at the 2019 AACE Annual Scientific and Clinical Congress in Los Angeles, CA. In patients with hyperglycemia, 15.4 and 50% in the low dose (LD) and high dose (HD) groups, respectively, were responders at last observed visit. In patients with hypertension, 41.7 and 63.6% in the LD and HD groups, respectively, were responders at last BP measurement. Back pain, edema, headache, pain in extremities and nausea were the most common TEAE [&lt;ulink linkID="2157498" linkType="Reference"&gt;2157498&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In  April 2016, data from a phase I trial  in  healthy volunteers  (expected n  = 124) were  reported. GR antagonism  tested by measuring relacorilant's ability to modulate prednisone's effects on serum osteocalcin, white blood cell counts, glucose metabolism and expression of the FKBP5 gene -- a marker of GR activation. Data demonstrated that with respect to all parameters, relacorilant was as potent a modulator of prednisone's activity as &lt;ulink linkID="43078" linkType="Drug"&gt;Korlym&lt;/ulink&gt; ( p&amp;lt; 0.0003). Also, pharmacokinetic data indicated that relacorilant was suitable for once-daily dosing [&lt;ulink linkID="1757177" linkType="Reference"&gt;1757177&lt;/ulink&gt;]. In September 2017, similar data were presented at the 19th RSC-SCI Medicinal Chemistry Symposium in Cambridge, UK [&lt;ulink linkID="1963048" linkType="Reference"&gt;1963048&lt;/ulink&gt;], [&lt;ulink linkID="1967161" linkType="Reference"&gt;1967161&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2014, a phase I trial was expected to begin in the following weeks [&lt;ulink linkID="1583174" linkType="Reference"&gt;1583174&lt;/ulink&gt;]. In September 2014, the first patient was enrolled and dosed in the trial to evaluate the safety and tolerability of the drug [&lt;ulink linkID="1608587" linkType="Reference"&gt;1608587&lt;/ulink&gt;].  In March 2015, preliminary positive data from the trial were reported. Data demonstrated that relacorilant reversed the activation of GR by the GR agonist prednisone [&lt;ulink linkID="1638809" linkType="Reference"&gt;1638809&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Solid tumors&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In December 2018, a randomized, open-label, single-group-assigned, 3-arm, phase II study (&lt;ulink linkID="363715" linkType="Protocol"&gt;NCT03776812&lt;/ulink&gt;; CORT125134-552) was planned to be initiated in January 2019, to assess the progression-free survival (PFS) in patients (expected n =177) with recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer treated with intermittent or continuous regimens of relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel alone. The primary endpoint was progression free survival 12 months from enrollment of last subject. At that time, the study was expected to complete in March 2023. In January 2019, the trial was initiated [&lt;ulink linkID="2105732" linkType="Reference"&gt;2105732&lt;/ulink&gt;]. In February 2019, the study  (expected n = 180) was underway  in the US and Europe   [&lt;ulink linkID="2123079" linkType="Reference"&gt;2123079&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2015, the company was planning to initiate a phase II trial in  cancer  [&lt;ulink linkID="1630027" linkType="Reference"&gt;1630027&lt;/ulink&gt;]. In April 2015, relacorilant was to be administered with a companion chemotherapeutic or hormonal agent to treat patients with a solid tumor cancer [&lt;ulink linkID="1646919" linkType="Reference"&gt;1646919&lt;/ulink&gt;], [&lt;ulink linkID="1710723" linkType="Reference"&gt;1710723&lt;/ulink&gt;]. By  April 2016, the  open-label phase I/II trial to investigate &lt;ulink linkID="29016" linkType="Drug"&gt;nab-paclitaxel&lt;/ulink&gt; in combination with relacorilant to treat any solid-tumor cancer susceptible to treatment with nab-paclitaxel,   had been initiated [&lt;ulink linkID="1757177" linkType="Reference"&gt;1757177&lt;/ulink&gt;]. In June 2016, the open-label, single-group-assigned, phase I/II trial (&lt;ulink linkID="260229" linkType="Protocol"&gt;NCT02762981&lt;/ulink&gt;; CORT125134-550) to evaluate the safety and efficacy of relacorilant in combination with &lt;ulink linkID="29016" linkType="Drug"&gt;nab-paclitaxel&lt;/ulink&gt; was ongoing in patients (expected n = 82) with solid tumors in the US. At that time, the trial was expected to complete in December 2018 [&lt;ulink linkID="1769080" linkType="Reference"&gt;1769080&lt;/ulink&gt;], [&lt;ulink linkID="1768988" linkType="Reference"&gt;1768988&lt;/ulink&gt;]. In January 2017, an expansion portion of the trial in patients with ovarian and triple-negative breast cancer was planned   [&lt;ulink linkID="1896408" linkType="Reference"&gt;1896408&lt;/ulink&gt;]. In March 2017, enrollment was ongoing and the company noted that 20-patient cohorts would be opened to assess the combination's efficacy in one or more solid tumors once a recommended combination dose would be identified. Other possible target indications included pancreatic cancer, cervical cancer and sarcoma [&lt;ulink linkID="1912768" linkType="Reference"&gt;1912768&lt;/ulink&gt;]. In December 2017, the company  opened an efficacy  cohort in patients with pancreatic cancer [&lt;ulink linkID="2011328" linkType="Reference"&gt;2011328&lt;/ulink&gt;]. In February 2018, the expansion cohorts in patients with ovarian and triple-negative breast cancer were expected to open later in 2018 [&lt;ulink linkID="2007707" linkType="Reference"&gt;2007707&lt;/ulink&gt;]. In May 2018, data from the expansion cohort of metastatic pancreatic cancer patients was expected in 2H18 [&lt;ulink linkID="2031871" linkType="Reference"&gt;2031871&lt;/ulink&gt;]. In June 2018, positive preliminary data from the initial, dose-finding portion of the trial in 35 patients were presented at the 54th ASCO Annual meeting in Chicago, IL. Neutropenia with dose delay &amp;gt;7 days and febrile neutropenia were the most common DLTs. Prophylactic G-CSF was being used in both the ongoing continuous and intermittent cohorts due to dose-limiting neutropenia. Of 22 evaluable patients, complete response, partial response, stable disease and progressive disease were observed in one, three, eight and ten patients, respectively. All patients with durable clinical benefit found to had &amp;gt;/= 60% GR positive cells [&lt;ulink linkID="2039437" linkType="Reference"&gt;2039437&lt;/ulink&gt;], [&lt;ulink linkID="2041222" linkType="Reference"&gt;2041222&lt;/ulink&gt;]. In October 2018, the company stated five of nine pancreatic patients from phase I/II study who received relacorilant in combination with nab-paclitaxel displayed durable disease control [&lt;ulink linkID="2077891" linkType="Reference"&gt;2077891&lt;/ulink&gt;]. In February 2019, further data were expected in the second quarter of 2019    [&lt;ulink linkID="2123079" linkType="Reference"&gt;2123079&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Prostate cancer&lt;/subtitle&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In October 2018, &lt;ulink linkID="26013" linkType="Company"&gt;University of Chicago&lt;/ulink&gt; in  collaboration with Corcept Therapeutics and   &lt;ulink linkID="20519" linkType="Company"&gt;National Cancer Institute&lt;/ulink&gt; initiated  an open-label, interventional,  single-group assigned, phase I trial (&lt;ulink linkID="353934" linkType="Protocol"&gt;NCT03674814&lt;/ulink&gt;; IRB18-0152; P50CA180995) in patients (expected n = 24) with mCRPC to assess the combination of relacorilant with &lt;ulink linkID="53981" linkType="Drug"&gt;enzalutamide&lt;/ulink&gt;. At that time, the trial was expected to start in November 2018 and complete in March 2020           [&lt;ulink linkID="2075548" linkType="Reference"&gt;2075548&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In September 2017, preclinical data were presented at the 19th RSC-SCI Medicinal Chemistry Symposium in Cambridge, UK. Relacorilant had excellent oral bioavailability in cynomologous monkeys and an 8 h half-life, an affinity of 81 nM was seen in a human TAT assay; however there was partial agonist activity in dogs [&lt;ulink linkID="1963048" linkType="Reference"&gt;1963048&lt;/ulink&gt;], [&lt;ulink linkID="1967161" linkType="Reference"&gt;1967161&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2017, in vivo data were presented at the 108th AACR Annual Meeting in Washington DC. In female Balb/c nude mice injected orthotopically with MDA-MB-231 cells in the right mammary fat pad and treated with paclitaxel (5 mg/kg iv q4d) + relacorilant (30 mg/kg daily, po) for 28 days, significant inhibition of tumor growth compared to vehicle-treated mice (p &amp;lt; 0.05) or to paclitaxel-treated mice (p &amp;lt; 0.05) was observed. In female Balb/c nude mice injected with SK-OV-3 cells in the right flank and treated with gemcitabine (80 mg/kg, intraperitoneal) + carboplatin (15 mg/kg, intraperitoneal) + relacorilant (20 mg/kg, intraperitoneal) on days 1, 2, 8 and 9, significant inhibition of tumor growth compared to vehicle-treated mice (p &amp;lt; 0.001) or to gemcitabine + carboplatin treated mice (p &amp;lt; 0.01) was observed [&lt;ulink linkID="1913695" linkType="Reference"&gt;1913695&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In  April 2016, data were reported in an animal model of colon cancer. Relacorilant to PD-1 monotherapy significantly slowed tumor progression (p= 0.013) [&lt;ulink linkID="1757177" linkType="Reference"&gt;1757177&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2015, preclinical data were presented at the 38th Annual San Antonio Breast Cancer Symposium in San Antonio, TX. &lt;ulink linkID="56072" linkType="Drug"&gt;CORT-108297&lt;/ulink&gt;, relacorilant and &lt;ulink linkID="69783" linkType="Drug"&gt;CORT-118335&lt;/ulink&gt; exhibited temporal antagonism of the expression of GR target genes encoding anti-apoptotic proteins such as SGK-1, MCL-1, and MKP-1/DUSP1. In vivo models, relacorilant and CORT-108297 were well-tolerated [&lt;ulink linkID="1721601" linkType="Reference"&gt;1721601&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By November 2015, relacorilant slowed tumor growth significantly in mouse models of triple-negative breast cancer and castration-resistant prostate cancer, when administered with a chemotherapeutic agent. In vitro, relacorilant similarly slowed the growth of ovarian cancer tumor cells. At that time, in vivo testing in mouse models of ovarian cancer was underway [&lt;ulink linkID="1710723" linkType="Reference"&gt;1710723&lt;/ulink&gt;].  By April 2016, further data had been reported. The mice implanted with TNBC tumor cells were treated with a combination of paclitaxel and relacorilant. &lt;ulink linkID="3628" linkType="Drug"&gt;Mifepristone&lt;/ulink&gt; in combination with paclitaxel served as a positive control. Data demonstrated that, as expected, the combination of mifepristone and paclitaxel significantly slowed tumor progression. However, the combination of relacorilant and paclitaxel slowed it even more (p=0.0004). In a similar experiment, castrated mice seeded with prostate cancer tumor cells were treated with either mifepristone or relacorilant. The outcome was comparable to the TNBC study: When combined with castration (which in humans would be achieved pharmacologically by the administration of an androgen receptor antagonist such as enzalutamide), mifepristone retarded tumor progression, but relacorilant had an even more pronounced effect (p= 0.037) [&lt;ulink linkID="1757177" linkType="Reference"&gt;1757177&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By January 2015, preclinical data were reported. Data demonstrated that the program had shown positive results both in in vitro and animal models of oncologic and metabolic disorders [&lt;ulink linkID="1630027" linkType="Reference"&gt;1630027&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In January 2016,  Corcept entered into an agreement with Chiltern to assist in the management of a phase II trial evaluating relacorilant for treatment of Cushing syndrome [&lt;ulink linkID="1912768" linkType="Reference"&gt;1912768&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="28807">Corcept Therapeutics Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3484">Cushings syndrome</Indication><StatusDate>2019-02-25T00:00:00.000Z</StatusDate><Source id="2123079" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28807">Corcept Therapeutics Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3484">Cushings syndrome</Indication><StatusDate>2019-02-25T00:00:00.000Z</StatusDate><Source id="2123079" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28807">Corcept Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3484">Cushings syndrome</Indication><StatusDate>2018-10-16T00:00:00.000Z</StatusDate><Source id="2081471" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28807">Corcept Therapeutics Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3484">Cushings syndrome</Indication><StatusDate>2016-12-13T00:00:00.000Z</StatusDate><Source id="1775589" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28807">Corcept Therapeutics Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2019-02-25T00:00:00.000Z</StatusDate><Source id="2123079" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28807">Corcept Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2019-01-28T00:00:00.000Z</StatusDate><Source id="2105732" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28807">Corcept Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3083">Peritoneal tumor</Indication><StatusDate>2019-01-28T00:00:00.000Z</StatusDate><Source id="2105732" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28807">Corcept Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2243">Fallopian tube cancer</Indication><StatusDate>2019-01-28T00:00:00.000Z</StatusDate><Source id="2105732" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28807">Corcept Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2016-04-28T00:00:00.000Z</StatusDate><Source id="1757177" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28807">Corcept Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2018-10-23T00:00:00.000Z</StatusDate><Source id="2075548" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28807">Corcept Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="249">Pancreas tumor</Indication><StatusDate>2017-12-31T00:00:00.000Z</StatusDate><Source id="2011328" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28807">Corcept Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2017-01-30T00:00:00.000Z</StatusDate><Source id="1896408" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="28807">Corcept Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3484">Cushings syndrome</Indication><StatusDate>2014-08-05T00:00:00.000Z</StatusDate><Source id="1583174" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28807">Corcept Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1005">Unidentified indication</Indication><StatusDate>2014-09-30T00:00:00.000Z</StatusDate><Source id="1608587" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28807">Corcept Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3484">Cushings syndrome</Indication><StatusDate>2015-01-29T00:00:00.000Z</StatusDate><Source id="1630027" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28807">Corcept Therapeutics Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3484">Cushings syndrome</Indication><StatusDate>2016-04-28T00:00:00.000Z</StatusDate><Source id="1757177" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28807">Corcept Therapeutics Inc</Company><Country id="HU">Hungary</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3484">Cushings syndrome</Indication><StatusDate>2016-12-13T00:00:00.000Z</StatusDate><Source id="1775589" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28807">Corcept Therapeutics Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3484">Cushings syndrome</Indication><StatusDate>2016-12-13T00:00:00.000Z</StatusDate><Source id="1775589" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28807">Corcept Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3484">Cushings syndrome</Indication><StatusDate>2016-06-30T00:00:00.000Z</StatusDate><Source id="1775589" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28807">Corcept Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2243">Fallopian tube cancer</Indication><StatusDate>2018-12-17T00:00:00.000Z</StatusDate><Source id="2105732" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28807">Corcept Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3083">Peritoneal tumor</Indication><StatusDate>2018-12-17T00:00:00.000Z</StatusDate><Source id="2105732" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28807">Corcept Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2017-01-30T00:00:00.000Z</StatusDate><Source id="1896408" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28807">Corcept Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2018-09-18T00:00:00.000Z</StatusDate><Source id="2075548" type="TRIALREG"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="28807">Corcept Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="3484">Cushings syndrome</Indication><AwardedIndication>Treatment of Cushing’s syndrome</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2019-04-17T00:00:00.000Z</MileStoneDate><Source id="2150182" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="28807">Corcept Therapeutics Inc</OwnerCompany><Country id="US">US</Country><Indication id="3484">Cushings syndrome</Indication><AwardedIndication>Treatment of endogenous Cushing syndrome</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2018-10-15T00:00:00.000Z</MileStoneDate><Source id="2114344" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="28807">Corcept Therapeutics Inc</OwnerCompany><Country id="US">US</Country><Indication id="249">Pancreas tumor</Indication><AwardedIndication>Treatment of pancreatic cancer</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2018-09-27T00:00:00.000Z</MileStoneDate><Source id="2077891" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00822"><Name>Glucocorticoid receptor</Name><SwissprotNumbers><Swissprot>O13186</Swissprot><Swissprot>O46567</Swissprot><Swissprot>O73673</Swissprot><Swissprot>P04150</Swissprot><Swissprot>P06536</Swissprot><Swissprot>P06537</Swissprot><Swissprot>P35547</Swissprot><Swissprot>P49115</Swissprot><Swissprot>P49843</Swissprot><Swissprot>P49844</Swissprot><Swissprot>P59667</Swissprot><Swissprot>P79269</Swissprot><Swissprot>P79686</Swissprot><Swissprot>Q5R9P5</Swissprot><Swissprot>Q95267</Swissprot><Swissprot>Q9N1U3</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2156603" linkType="reference" linkID="2156603"&gt;2156603&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>Cn1cc(cn1)S(=O)(=O)N2CCC3=Cc4c(cnn4c5ccc(cc5)F)C[C@@]3(C2)C(=O)c6cc(ccn6)C(F)(F)F</Smiles></StructureSmiles><PatentFamilies><PatentFamily id="2640793" number="WO-2013177559" title="Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators"/><PatentFamily id="2799741" number="WO-2014141084" title="Device and method for determining vital signs of a subject"/><PatentFamily id="3780144" number="WO-2017151613" title="The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors"/><PatentFamily id="3979679" number="WO-2018049255" title="Glucocorticoid receptor modulators to treat pancreatic cancer"/><PatentFamily id="4219392" number="WO-2018183947" title="Glucocorticoid receptor modulators to treat cervical cancer"/><PatentFamily id="4321579" number="WO-2018236749" title="Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>3</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tamura Corp" id="1020381"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Corcept Therapeutics Inc" id="28807"/><CountAsOwner>6</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Royal Philips Electronics" id="30941"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>